扩张型心肌病猝死风险分层的个体化:过去、现在与未来
本文综述扩张型心肌病(DCM)猝死风险分层的演变,指出DANISH研究提示许多DCM患者植入ICD不延长寿命,仅用左心室射血分数(LVEF)选择患者存在局限。文章汇总心肌纤维化、微伏T波交替和基因检测等新方法,认为未来5至10年这些技术有望整合入现有流程。
要点
- DANISH研究提示许多DCM患者植入ICD不延长寿命,需更精准识别心律失常死亡高风险者。
- LVEF作为唯一选择标准存在局限:部分院外心脏骤停患者LVEF未显著降低,低LVEF者多死于非猝死原因。
- 心肌纤维化、微伏T波交替和基因检测是有前景的风险分层方法,但尚未常规用于临床。
核心结论
- 仅用左心室射血分数选择DCM患者植入ICD存在局限,需整合心肌纤维化、微伏T波交替和基因检测等以形成更敏感、特异且具成本效益的选择方法。
研究设计与样本
- 本文为综述,基于DANISH研究结果及注册数据、荟萃分析和遗传学研究等文献汇总DCM猝死风险分层方法。
主要发现
- DANISH研究提示许多DCM患者植入ICD不增加寿命。
- 注册数据显示许多DCM合并院外心脏骤停患者左心室射血分数并未显著降低。
- 许多左心室射血分数降低患者死于非猝死原因。
- 约30%患者经钆延迟增强心血管磁共振识别出壁内纤维化,其在左心室射血分数之外对预测猝死事件提供增量价值。
- 微伏T波交替获大型荟萃分析支持,突出其阴性预测价值。
关键数值与推荐
- 左心室射血分数一直被用作选择DCM患者植入ICD进行一级预防的关键标准。
- 壁内纤维化约见于30%患者,可在左心室射血分数之外增量预测猝死事件。
- LMNA突变约占特发性DCM的6%,因表型恶性常促使更积极管理。
临床怎么用
- DCM患者选择ICD时不应仅依赖左心室射血分数,应综合评估心肌纤维化、微伏T波交替和基因检测结果。
- 对携带LMNA突变等恶性表型患者可考虑更积极的管理策略。
局限性
- 心肌纤维化和微伏T波交替尚未常规用于临床风险分层。
- 需更多随机试验数据指导具有这些特征患者的治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Results from the DANISH Study (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heat Failure on Mortality) suggest that for many patients with dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase longevity. Accurate identification of patients who are more likely to die of an arrhythmia and less likely to die of other causes is required to ensure improvement in outcomes and wise use of resources. Until now, left ventricular ejection fraction has been used as a key criterion for selecting patients with DCM for an implantable cardioverter-defibrillator for primary prevention purposes. However, registry data suggest that many patients with DCM and an out-of-hospital cardiac arrest do not have a markedly reduced left ventricular ejection fraction. In addition, many patients with reduced left ventricular ejection fraction die of nonsudden causes of death. Methods to predict a higher or lower risk of sudden death include the detection of myocardial fibrosis (a substrate for ventricular arrhythmia), microvolt T-wave alternans (a marker of electrophysiological vulnerability), and genetic testing. Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic resonance imaging in ≈30% of patients and provides incremental value in addition to left ventricular ejection fraction for the prediction of sudden cardiac death events. Microvolt T-wave alternans represents another promising predictor, supported by large meta-analyses that have highlighted the negative predictive value of this test. However, neither of these strategies have been routinely adopted for risk stratification in clinical practice. More convincing data from randomized trials are required to inform the management of patients with these features. Understanding of the genetics of DCM and how specific mutations affect arrhythmic risk is also rapidly increasing. The finding of a mutation in lamin A/C, the cause of ≈6% of idiopathic DCM, commonly underpins more aggressive management because of the malignant nature of the associated phenotype. With the expansion of genetic sequencing, the identification of further high-risk mutations appears likely, leading to better-informed clinical decision making and providing insight into disease mechanisms. Over the next 5 to 10 years, we expect these techniques to be integrated into the existing algorithm to form a more sensitive, specific, and cost-effective approach to the selection of patients with DCM for implantable cardioverter-defibrillator implantation.
引用
- Halliday BP, Cleland JGF, Goldberger JJ, et al. Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future. Circulation. 2017. PMID: 28696268. doi:10.1161/CIRCULATIONAHA.116.027134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。